Literature DB >> 12174870

The antibacterial drug taurolidine induces apoptosis by a mitochondrial cytochrome c-dependent mechanism.

Zhiyong Han1, Iole Ribbizi, Panayotis Pantazis, James Wyche, James Darnowski, Paul Calabresi.   

Abstract

The antibacterial agent taurolidine (TRD) has been used as a lavage antibiotic to prevent development of peritonitis in patients after surgery. We recently showed that TRD induced growth arrest and apoptosis of a variety of cultured cell lines derived from human solid tumors and also significantly inhibited the growth of human ovarian tumors in a mouse model. In this report, we present data to show that TRD, at concentrations below the doses that are used to treat patients in the clinic, induces apoptosis of human leukemia HL-60 cells by a mitochondrial cytochrome c-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174870

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Comparative analysis of cell death induction by Taurolidine in different malignant human cancer cell lines.

Authors:  Ansgar M Chromik; Adrien Daigeler; Daniel Bulut; Annegret Flier; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Peter R Ritter; Ulrich Mittelkötter; Stephan A Hahn; Waldemar Uhl
Journal:  J Exp Clin Cancer Res       Date:  2010-03-07

2.  Effects of increasing doses of a bolus injection and an intravenous long-term therapy of taurolidine on subcutaneous (metastatic) tumor growth in rats.

Authors:  Chris Braumann; Marco Schoenbeck; Charalambos Menenakos; Maik Kilian; Christoph A Jacobi
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice.

Authors:  Ansgar Michael Chromik; Sebastian Huss; Hayssam Osseili; Adrien Daigeler; Sabine Kersting; Dominique Sülberg; Ulrich Mittelkötter; Thomas Herdegen; Waldemar Uhl; Annette M Müller
Journal:  J Carcinog       Date:  2010-04-16

4.  Gene expression analysis of cell death induction by taurolidine in different malignant cell lines.

Authors:  Ansgar M Chromik; Stephan A Hahn; Adrien Daigeler; Annegret Flier; Daniel Bulut; Christina May; Kamran Harati; Jan Roschinsky; Dominique Sülberg; Dirk Weyhe; Ulrich Mittelkötter; Waldemar Uhl
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

5.  Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case.

Authors:  Chris Braumann; Goetz Winkler; Patrick Rogalla; Charalambos Menenakos; Christoph A Jacobi
Journal:  World J Surg Oncol       Date:  2006-06-24       Impact factor: 2.754

6.  Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells.

Authors:  Georg Eschenburg; Christian Luckert; Konrad Reinshagen; Robert Bergholz
Journal:  Genes Cancer       Date:  2014-11

7.  Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial.

Authors:  Chris Braumann; Carsten N Gutt; Johannes Scheele; Charalambos Menenakos; Wilhelm Willems; Joachim M Mueller; Christoph A Jacobi
Journal:  World J Surg Oncol       Date:  2009-03-23       Impact factor: 2.754

8.  TRAIL and Taurolidine induce apoptosis and decrease proliferation in human fibrosarcoma.

Authors:  Adrien Daigeler; Christina Brenzel; Daniel Bulut; Anne Geisler; Christoph Hilgert; Marcus Lehnhardt; Hans U Steinau; Annegret Flier; Lars Steinstraesser; Ludger Klein-Hitpass; Ulrich Mittelkötter; Waldemar Uhl; Ansgar M Chromik
Journal:  J Exp Clin Cancer Res       Date:  2008-12-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.